With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients ...

OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

Adeno-associated virus (AAV)–mediated gene therapy was one of the focal points of this year's Muscular Dystrophy Association conference. Here, Barry Byrne, MD, PhD, University of Florida, speaks to ...

Researchers have found a promising new method for gene therapy. They successfully restarted inactive genes by bringing them closer to genetic switches on the DNA called enhancers. The intermediate ...

A genetic variant carried by at least one-fifth of the population may do far more than raise the odds of developing Alzheimer ...

Gene therapy approaches include gene replacement, suppression, and editing, each matched to specific genetic mechanisms in hereditary hearing loss. Preclinical studies in rodent models show promise, ...

Ocugen OCGN is pushing three retinal gene therapy programs toward late-stage milestones, with multiple data readouts and ...

Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...

Nemours Children's Hospital is now offering Lyfgenia gene therapy. The treatment aims to reduce pain crises and hospital visits for young patients.

The last available hemophilia gene therapy is temporarily unavailable, according to CSL Behring.  | The company is working ...

Issued on behalf of Avaí Bio, Inc.Companies mentioned in this article: Avaí Bio (OTCQB: AVAI), FibroBiologics (NASDAQ: FBLG), Fate Therapeutics ...